Clinical trial
A Prospective, Multicenter, Open Label, Single Arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension
NCT03492177 is registered in ClinicalTrials.gov with Actelion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Open Label, Single Arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension
- Lead sponsor
- Actelion
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 23, 2018
- Completion date
- December 31, 2026
- Enrollment
- 63 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.